Timeline
Beximco Pharmaceuticals
Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate
Beximco Pharma delivers first doses of generic cystic fibrosis treatment at 96% discount to US price
More in Pharma
Shield Therapeutics takes full US control of ACCRUFeR
The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.